Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

Relapse-free survival at 5 months was of 72% for negative patients and of 53% for positive patients, but overall the impact on relapse-free survival did not reach statistical significance (Supplementary Fig. 2 A).

also in 111,027 other papers